We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Patch-Based Ebolavirus Diagnostic to Help Quickly Identify and Treat Infected Individuals

By LabMedica International staff writers
Posted on 22 Aug 2023
Print article
Image: The SatioDot dried blood spot collection patch (Photo courtesy of Satio)
Image: The SatioDot dried blood spot collection patch (Photo courtesy of Satio)

A groundbreaking diagnostic that combines a patch-based blood collection device with a sensitive and rapid immunoassay for ebolavirus into a single device will allow community health workers to quickly identify and treat infected individuals in remote settings.

The novel, single-use, rapid ebolavirus diagnostic will combine Satio, Inc.’s (Boston, MA, USA) patch-based blood collection device with an ebolavirus immunoassay from Institut Pasteur de Dakar (Dakar, Senegal). Satio is working on a suite of patch-based platforms, including SatioDot optimized for dried blood spots, and SatioDraw designed for comprehensive whole blood collection, which can cater to an extensive array of lab-based tests. These platforms employ a lancet to gather blood from the upper arm, channeling it into the patch. Satio is now accelerating the development of an integrated blood draw and diagnostic platform with the potential to extend its capabilities for identifying other critical blood-borne pathogens, such as HIV and syphilis.

Satio's groundbreaking designs, covered by patent protection, provide patients with access to simple and cost-effective blood collection options. These solutions facilitate blood extraction, reagent mixing, and the identification of an array of pathogens, all achieved through a patch affixed to the arm. In a remarkable extension, Satio's patch technology also holds the potential for the painless administration of drugs and vaccines. Consequently, this innovation holds the promise to mitigate or even eliminate the necessity for needles and medical professional intervention. By doing away with conventional fingerstick blood samples and the associated external blood sample manipulation, Satio's trailblazing innovation reduces exposure to bloodborne pathogens. Simultaneously, it offers an exceptional, budget-friendly diagnostic tool for easy deployment at the point of need, thereby advancing patient outcomes and restricting the spread of ebolavirus.

Related Links:
Satio, Inc.
Institut Pasteur de Dakar 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.